Clemens-martin M. Wendtner

Clemens-martin M. Wendtner

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 110 publications

A Comprehensive Review of the Role of Zanubrutinib for Patients with Chronic Lymphocytic Leukemia.

A Comprehensive Review of the Role of Zanubrutinib for Patients with Chronic Lymphocytic Leukemia.

Journal: Oncology and therapy

Published: January 28, 2026

Risk factors for severe post-COVID condition in children, adolescents, and young adults.

Risk factors for severe post-COVID condition in children, adolescents, and young adults.

Journal: European journal of pediatrics

Published: December 14, 2025

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

Journal: The New England journal of medicine

Published: December 08, 2025

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial.

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcome analysis of the CLL13/GAIA trial.

Journal: Blood

Published: October 22, 2025

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Journal: Blood

Published: October 22, 2025

The HLH-Risk-Calculator is a machine learning-based tool to predict course & mortality of secondary hemophagocytic lymphohistiocytosis.

The HLH-Risk-Calculator is a machine learning-based tool to predict course & mortality of secondary hemophagocytic lymphohistiocytosis.

Journal: Intensive care medicine

Published: October 07, 2025

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.

The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.

Journal: Blood

Published: February 24, 2025

Clinical trials in early-stage CLL: what has been learned and what's next?

Clinical trials in early-stage CLL: what has been learned and what's next?

Journal: Leukemia & lymphoma

Published: November 29, 2024

Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.

Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 27, 2024

SARS-COV-2 Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab in Haematological, Immunocompromised Patients in the Omicron Era.

SARS-COV-2 Pre-Exposure Prophylaxis With Tixagevimab-Cilgavimab in Haematological, Immunocompromised Patients in the Omicron Era.

Journal: European journal of haematology

Published: September 23, 2024

Implementation of an Immunoassay Based on the MVA-T7pol-Expression System for Rapid Identification of Immunogenic SARS-CoV-2 Antigens: A Proof-of-Concept Study.

Implementation of an Immunoassay Based on the MVA-T7pol-Expression System for Rapid Identification of Immunogenic SARS-CoV-2 Antigens: A Proof-of-Concept Study.

Journal: International journal of molecular sciences

Published: September 08, 2024

Burden of COVID-19 in immunocompromised patients in Germany: a retrospective, observational Study on Health Insurance Data from 2021 to 2022.

Burden of COVID-19 in immunocompromised patients in Germany: a retrospective, observational Study on Health Insurance Data from 2021 to 2022.

Journal: Infection

Published: August 28, 2024

Showing 1-12 of 110

Last Updated: 09/26/2026